CRBU vs NKTX
CRBU: Caribou develops off-the-shelf CRISPR-engineered CAR-T cell therapies designed to make cellular immunotherapy faster, cheaper, and accessible to more blood cancer patients. NKTX: Nkarta is a clinical-stage biotech developing off-the-shelf, engineered natural killer (NK) cell therapies aimed at treating autoimmune diseases through targeted B-cell depletion.
Side-by-side fundamentals
| Metric | CRBU | NKTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $1.66 | $2.41 | |
| Market cap as of 2026-07-23 | $165M | $172M | |
| Net margin as of 2026-07-23 | -1189.1% | -17566.7% | CRBU higher |
| Operating margin as of 2026-07-23 | -1257.4% | -19250.0% | CRBU higher |
| ROE as of 2026-07-23 | -100.1% | -30.9% | NKTX higher |
| ROA as of 2026-07-23 | -72.0% | -24.2% | NKTX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | +13.0% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -7.0% | n/a | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-07-23 | 2.33 | 0.92 | |
| 1-year return as of 2026-07-22 close | -20.3% | +34.4% | NKTX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.